17-AAG: mechanisms of antitumour activity

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Expert Opinion on Investigational Drugs

• Publication date

  2005-11-25

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1517/13543784.14.12.1471PMID 16307487
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.

  2005cited by this paper
• Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies.

  2005cited by this paper
• Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent

  2004cited by this paper
• Altered Hsp90 function in cancer: a unique therapeutic opportunity.

  2004cited by this paper
• Hsp90: an emerging target for breast cancer therapy

  2004cited by this paper
• Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells.

  2003cited by this paper
• Regulation of 17-AAG-induced apoptosis: role of Bcl-2, Bcl-XL, and Bax downstream of 17-AAG-mediated down-regulation of Akt, Raf-1, and Src kinases.

  2003cited by this paper
• Loss of PTEN promotes tumor development in malignant melanoma.

  2003influential reference
• The influence of the src‐family kinases, Lck and Fyn, on T cell differentiation, survival and activation

  2003cited by this paper
• Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.

  2003cited by this paper
• Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids.

  2003cited by this paper
• Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway.

  2002cited by this paper
• Heat shock protein 90 inhibition by 17-allylamino-17- demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer.

  2002cited by this paper
• Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2

  2002cited by this paper
• Hsp90 Regulates a von Hippel Lindau-independent Hypoxia-inducible Factor-1α-degradative Pathway*

  2002cited by this paper
• Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228.

  2002cited by this paper
• Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts.

  2001cited by this paper
• Hsp90: a specialized but essential protein-folding tool.

  2001cited by this paper
• Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis.

  2001cited by this paper
• Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-

  2001cited by this paper
• p53 from complexity to simplicity: mutant p53 stabilization, gain‐of‐function, and dominant‐negative effect

  2000cited by this paper
• Modulation of metastasis phenotypes of non-small cell lung cancer cells by 17-allylamino 17-demethoxy geldanamycin.

  2000cited by this paper
• Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest.

  2000cited by this paper
• DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90.

  1999cited by this paper
• Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone.

  1997cited by this paper
• Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90.

  1996cited by this paper
• Herbimycin A Induces the 20 S Proteasome- and Ubiquitindependent Degradation of Receptor Tyrosine Kinases (*)

  1995cited by this paper
• Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation.

  1994cited by this paper

• Modulation of Heat Shock Proteins Levels in Health and Disease: An Integrated Perspective in Diagnostics and Therapy

  2025cites this paper
• Heat shock proteins as hallmarks of cancer: insights from molecular mechanisms to therapeutic strategies

  2024cites this paper
• Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours

  2021cites this paper
• Selective inhibitors of zinc-dependent histone deacetylases. Therapeutic targets relevant to cancer.

  2015cites this paper
• Targeting Heat Shock Proteins by Phenethyl Isothiocyanate Results in Cell-Cycle Arrest and Apoptosis of Human Breast Cancer Cells

  2013cites this paper
• Méthodes et compositions pharmaceutiques pour le traitement de malignités hématologiques réfractaires

  2013cites this paper
• Intracellular refolding assay.

  2012cites this paper
• Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise

  2010cites this paper
• Targeting the DNA damage response in cancer.

  2009cites this paper
• Matrix metalloproteinase inhibitors as anticancer agents.

  2008cites this paper
• Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents

  2007cites this paper
• Phase I and Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients with Refractory Advanced Cancers

  2007cites this paper
• The power and promise of “rewiring” the mitogen-activated protein kinase network in prostate cancer therapeutics

  2007cites this paper
• HU-331: a cannabinoid quinone, with uncommon cytotoxic properties and low toxicity

  2007cites this paper
• Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond

  2007cites this paper
• Mechanisms of Disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy

  2006cites this paper
• The potential of proteasome inhibition in the treatment of colon cancer

  2006cites this paper
• Chromatin-modulating agents as epigenetic anticancer drugs--'the die is cast'.

  2006cites this paper